Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Open Access
- 1 January 2014
- journal article
- review article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 7 (1), 72
- https://doi.org/10.1186/s40413-014-0050-z
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticariaAllergy, 2014
- Chronic Spontaneous UrticariaImmunology and Allergy Clinics of North America, 2014
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaThe New England Journal of Medicine, 2013
- Effects of Omalizumab Treatment in Patients With Refractory Chronic UrticariaAllergy, Asthma & Immunology Research, 2012
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- The German version of the chronic urticaria quality‐of‐life questionnaire: factor analysis, validation, and initial clinical findingsAllergy, 2009
- Treatment of chronic autoimmune urticaria with omalizumabJournal of Allergy and Clinical Immunology, 2008
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994